Pancreatic cancer cell exosome-mediated macrophage reprogramming and the role of MicroRNAs 155 and 125b2 transfection using nanoparticle delivery systems

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Su, Mei Ju ^a   Aldawsari, Hibah ^b   Amiji, Mansoor ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIC ACID; MICRORNA; NANOPARTICLE;

ANIMAL; CELL COMMUNICATION; CELL LINE; COCULTURE; EXOSOME; GENETIC TRANSFECTION; HUMAN; MACROPHAGE; METABOLISM; MOUSE; PANCREAS; PANCREAS TUMOR; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; CELL COMMUNICATION; CELL LINE; CELL LINE, TUMOR; COCULTURE TECHNIQUES; EXOSOMES; HUMANS; HYALURONIC ACID; MACROPHAGES; MICE; MICRORNAS; NANOPARTICLES; PANCREAS; PANCREATIC NEOPLASMS; TRANSFECTION;

EID: 84979211644     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30110     Document Type: Article

References (50)

1. Bijlsma, M. F. & van Laarhoven, H. W. The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. Cancer metastasis reviews, doi: 10.1007/s10555-014-9541-1 (2015).
2. Winter, J. M. et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Annals of surgical oncology 19, 169-175, doi: 10.1245/s10434-011-1900-3 (2012).
3. Hidalgo, M. Pancreatic cancer. The New England journal of medicine 362, 1605-1617, doi: 10.1056/NEJMra0901557 (2010).
4. Neoptolemos, J. P. Adjuvant treatment of pancreatic cancer. European journal of cancer 47 Suppl 3, S378-380, doi: 10.1016/S0959- 8049(11)70210-6 (2011).
5. Takayama, R. et al. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma. Journal of gastroenterology 45, 52-59, doi: 10.1007/s00535-009-0114-y (2010).
6. Erkan, M. et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nature reviews. Gastroenterology & hepatology 9, 454-467, doi: 10.1038/nrgastro.2012.115 (2012).
7. Yin-Xu, Z., Xiao Mei, L., Teng, Z., Yu, L. & Jun Hua, Z. Influence of tumor associated macrophages on biological function of SW620 cell. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 33, 71-75, doi: 10.3881/j.issn.1000-503X.2011.01.015 (2011).
8. Helm, O. et al. Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis. International journal of cancer. Journal international du cancer 135, 843-861, doi: 10.1002/ijc.28736 (2014).
9. Rogers, T. L. & Holen, I. Tumour macrophages as potential targets of bisphosphonates. Journal of translational medicine 9, 177, doi: 10.1186/1479-5876-9-177 (2011).
10. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436-444, doi: 10.1038/nature07205 (2008).
11. Mantovani, A. et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends in immunology 25, 677-686, doi: 10.1016/j.it.2004.09.015 (2004).
12. Quatromoni, J. G. & Eruslanov, E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. American journal of translational research 4, 376-389 (2012).
13. Schiavoni, G., Gabriele, L. & Mattei, F. The tumor microenvironment: a pitch for multiple players. Frontiers in oncology 3, 90, doi: 10.3389/fonc.2013.00090 (2013).
14. Tran, T. H., Rastogi, R., Shelke, J. & Amiji, M. M. Modulation of Macrophage Functional Polarity towards Anti-Inflammatory Phenotype with Plasmid DNA Delivery in CD44 Targeting Hyaluronic Acid Nanoparticles. Scientific reports 5, 16632, doi: 10.1038/srep16632 (2015).
15. Wynn, T. A., Chawla, A. & Pollard, J. W. Macrophage biology in development, homeostasis and disease. Nature 496, 445-455, doi: 10.1038/nature12034 (2013).
16. Mantovani, A. & Sica, A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Current opinion in immunology 22, 231-237, doi: 10.1016/j.coi.2010.01.009 (2010).
17. Kleeff, J. et al. Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. International journal of cancer. Journal international du cancer 81, 650-657 (1999).
18. Puolakkainen, P. et al. Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression. Medical oncology 31, 884, doi: 10.1007/s12032-014-0884-9 (2014).
19. Mielgo, A. & Schmid, M. C. Impact of tumour associated macrophages in pancreatic cancer. BMB reports 46, 131-138 (2013).
20. Singh, A., Talekar, M., Raikar, A. & Amiji, M. Macrophage-targeted delivery systems for nucleic acid therapy of inflammatory diseases. Journal of controlled release: official journal of the Controlled Release Society 190, 515-530, doi: 10.1016/j.jconrel.2014.04.021 (2014).
21. Beach, A., Zhang, H. G., Ratajczak, M. Z. & Kakar, S. S. Exosomes: an overview of biogenesis, composition and role in ovarian cancer. Journal of ovarian research 7, 14, doi: 10.1186/1757-2215-7-14 (2014).
22. Marleau, A. M., Chen, C. S., Joyce, J. A. & Tullis, R. H. Exosome removal as a therapeutic adjuvant in cancer. Journal of translational medicine 10, 134, doi: 10.1186/1479-5876-10-134 (2012).
23. Yang, C. & Robbins, P. D. The roles of tumor-derived exosomes in cancer pathogenesis. Clinical & developmental immunology 2011, 842849, doi: 10.1155/2011/842849 (2011).
24. Wang, W. & Lotze, M. T. Good things come in small packages: exosomes, immunity and cancer. Cancer gene therapy 21, 139-141, doi: 10.1038/cgt.2014.14 (2014).
25. Zhang, H. G. & Grizzle, W. E. Exosomes and cancer: a newly described pathway of immune suppression. Clinical cancer research : an official journal of the American Association for Cancer Research 17, 959-964, doi: 10.1158/1078-0432.CCR-10-1489 (2011).
26. Vlassov, A. V., Magdaleno, S., Setterquist, R. & Conrad, R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochimica et biophysica acta 1820, 940-948, doi: 10.1016/j.bbagen.2012.03.017 (2012).
27. Bobrie, A., Colombo, M., Raposo, G. & Thery, C. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic 12, 1659-1668, doi: 10.1111/j.1600-0854.2011.01225.x (2011).
28. Milane, L., Singh, A., Mattheolabakis, G., Suresh, M. & Amiji, M. M. Exosome mediated communication within the tumor microenvironment. Journal of controlled release : official journal of the Controlled Release Society 219, 278-294, doi: 10.1016/j. jconrel.2015.06.029 (2015).
29. Kharaziha, P., Ceder, S., Li, Q. & Panaretakis, T. Tumor cell-derived exosomes: a message in a bottle. Biochimica et biophysica acta 1826, 103-111, doi: 10.1016/j.bbcan.2012.03.006 (2012).
30. Muralidharan-Chari, V., Clancy, J. W., Sedgwick, A. & D'Souza-Schorey, C. Microvesicles: mediators of extracellular communication during cancer progression. Journal of cell science 123, 1603-1611, doi: 10.1242/jcs.064386 (2010).
31. Calin, G. A. & Croce, C. M. MicroRNA-cancer connection: the beginning of a new tale. Cancer research 66, 7390-7394, doi: 10.1158/0008-5472.CAN-06-0800 (2006).
32. Schwarzenbach, H., Nishida, N., Calin, G. A. & Pantel, K. Clinical relevance of circulating cell-free microRNAs in cancer. Nature reviews. Clinical oncology 11, 145-156, doi: 10.1038/nrclinonc.2014.5 (2014).
33. Acunzo, M., Romano, G., Wernicke, D. & Croce, C. M. MicroRNA and cancer-a brief overview. Advances in biological regulation 57, 1-9, doi: 10.1016/j.jbior.2014.09.013 (2015).
34. Ling, H., Fabbri, M. & Calin, G. A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nature reviews. Drug discovery 12, 847-865, doi: 10.1038/nrd4140 (2013).
35. Strachan, D. C. et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells. Oncoimmunology 2, e26968, doi: 10.4161/onci.26968 (2013).
36. Faraoni, I., Antonetti, F. R., Cardone, J. & Bonmassar, E. miR-155 gene: a typical multifunctional microRNA. Biochimica et biophysica acta 1792, 497-505, doi: 10.1016/j.bbadis.2009.02.013 (2009).
37. Esquela-Kerscher, A. & Slack, F. J. Oncomirs - microRNAs with a role in cancer. Nature reviews. Cancer 6, 259-269, doi: 10.1038/nrc1840 (2006).
38. Zonari, E. et al. A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. Blood 122, 243-252, doi: 10.1182/blood-2012-08-449306 (2013).
39. Chaudhuri, A. A. et al. MicroRNA-125b potentiates macrophage activation. Journal of immunology 187, 5062-5068, doi: 10.4049/jimmunol.1102001 (2011).
40. Giray, B. G. et al. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. Molecular biology reports 41, 4513-4519, doi: 10.1007/s11033-014-3322-3 (2014).
41. Jiang, L. et al. Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC cancer 10, 318, doi: 10.1186/1471-2407-10-318 (2010).
42. Banzhaf-Strathmann, J. & Edbauer, D. Good guy or bad guy: the opposing roles of microRNA 125b in cancer. Cell communication and signaling: CCS 12, 30, doi: 10.1186/1478-811X-12-30 (2014).
43. Graff, J. W., Dickson, A. M., Clay, G., McCaffrey, A. P. & Wilson, M. E. Identifying functional microRNAs in macrophages with polarized phenotypes. The Journal of biological chemistry 287, 21816-21825, doi: 10.1074/jbc.M111.327031 (2012).
44. Ganesh, S., Iyer, A. K., Morrissey, D. V. & Amiji, M. M. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 34, 3489-3502, doi: 10.1016/j.biomaterials.2013.01.077 (2013).
45. He, Y. et al. Polyethyleneimine/DNA polyplexes with reduction-sensitive hyaluronic acid derivatives shielding for targeted gene delivery. Biomaterials 34, 1235-1245, doi: 10.1016/j.biomaterials.2012.09.049 (2013).
46. Han, H. S. et al. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo. Journal of controlled release: official journal of the Controlled Release Society 168, 105-114, doi: 10.1016/j. jconrel.2013.02.022 (2013).
47. Yu, H. et al. Overcoming endosomal barrier by amphotericin B-loaded dual pH-responsive PDMA-b-PDPA micelleplexes for siRNA delivery. ACS nano 5, 9246-9255, doi: 10.1021/nn203503h (2011).
48. Yang, X. et al. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Scientific reports 5, 8509, doi: 10.1038/srep08509 (2015).
49. Ganesh, S., Iyer, A. K., Gattacceca, F., Morrissey, D. V. & Amiji, M. M. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. Journal of controlled release: official journal of the Controlled Release Society 172, 699-706, doi: 10.1016/j.jconrel.2013.10.016 (2013).
50. Yang, X. et al. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer. Pharmaceutical research, doi: 10.1007/s11095-014-1602-1 (2014).